This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
NCOA7 / Nuclear receptor coactivator 7 · IHC design guide
Design Immunohistochemistry for NCOA7
Use cervical squamous epithelium as a high-staining reference for NCOA7 paraffin-section IHC (HPA tissue IHC). Compare nuclear and cytoplasmic staining (HPA tissue IHC) with matched controls (standard IHC practice), and check epitope coverage across 7 isoforms (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
NCOA7 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear and cytoplasmic staining (HPA tissue IHC) | |
| Staining pattern | Nuclear and cytoplasmic signal in CNS, squamous cells and nerves (HPA tissue IHC) | |
| Antigen retrieval | Tris-EDTA pH 8.0 HIER, heat-mediated (datasheet A05814-1) | |
| Positive control | Cervix+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A05814-1) | |
| Caveat | Staining and RNA show low consistency; validate specificity (HPA tissue IHC) | |
| Regulation | Estradiol promotes nuclear localization (UniProt) | |
| Isoform / epitope | 7 isoforms; epitope coverage is unspecified (UniProt) |
Section 1
Recommended NCOA7 IHC & IF Protocols
The catalog antibody uses heat-mediated Tris-EDTA retrieval at pH 8.0 (datasheet A05814-1). The published paraffin-section IHC protocols below cover breast and oral cancer tissue (PMC11063752; PMC12819905; PMC5312364).
| Sample | Paraffin-embedded Human brain tissue; fixative not specified (datasheet A05814-1) |
| Fixation | Image fixative and duration unreported (datasheet A05814-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Tris-EDTA pH 8.0 (datasheet A05814-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-NCOA7, 1:100-1:300 (datasheet A05814-1) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | NCOA7-positive staining in squamous epithelial cells of cervix (HPA tissue IHC: High). HPA tissue profile: Nuclear and cytoplasmic expression in several cell types, mainly in the CNS, squamous epithelia and peripheral nerves. No signal in the no-primary control. |
💡Decision noteStart with Tris-EDTA pH 8.0 retrieval (datasheet A05814-1); compare citrate pH 6.0 (PMC11063752) or microwave EDTA retrieval (PMC5312364) during optimization.
Section 2
What Is the Expected NCOA7 Staining Pattern?
NCOA7 should show nuclear and cytoplasmic IHC staining in selected cell types, especially CNS cells and squamous epithelia (HPA tissue IHC). Nucleoplasm and nuclear bodies are the main ICC/IF locations, with additional Golgi staining (HPA subcellular ICC/IF). NCOA7 has no transmembrane segment (UniProt Q8NI08 topology). Interpret tissue staining cautiously: HPA rates it Approved but reports low consistency with RNA data and pending external verification (HPA tissue IHC).
| Nuclear and cytoplasmic signal in cervical squamous epithelial cells, with stronger staining than nearby unstained cells. | This fits a positive IHC result: HPA reports High staining in cervical squamous epithelial cells and a nuclear and cytoplasmic tissue profile (HPA tissue IHC). Judge the cell type and compartment together; intensity alone does not establish specificity (general IHC practice). |
| Signal is confined to cell borders or extracellular material, with no convincing nuclear or cytoplasmic staining. | This is a compartment mismatch with the reported tissue profile (HPA tissue IHC). NCOA7 has no transmembrane segment (UniProt Q8NI08 topology). Check morphology and controls before calling it positive; the pattern may reflect staining artefact (general IHC practice). |
| Strong staining appears chiefly in adipocytes or bone marrow hematopoietic cells. | HPA reports NCOA7 as Not detected in those cell populations (HPA tissue IHC). Consider antibody cross-reactivity or endogenous detection activity, and compare an appropriate negative control before assigning the signal to NCOA7 (general IHC practice). |
| Weak colour spreads across cells and tissue spaces without clear cellular boundaries. | Diffuse background does not establish NCOA7 localisation (general IHC practice). Assess blocking, washes and detection controls; a true call should resolve to plausible cells and nuclear or cytoplasmic compartments (HPA tissue IHC; general IHC practice). |
| Cervical squamous epithelial cells show no detectable signal. | That conflicts with HPA's High staining report for those cells (HPA tissue IHC). Check the antibody's IHC-P instructions and control performance before interpreting the specimen as negative; HPA also flags low RNA–staining consistency (HPA tissue IHC; general IHC practice). |
💡Expected NCOA7 appearanceCall an IHC result positive when selected cells show discernible nuclear and cytoplasmic staining—potentially High in cervical squamous epithelium (HPA tissue IHC); border-only or diffuse, cell-unresolved colour is suspect (UniProt Q8NI08 topology; general IHC practice).
| Cell type and tissue | HPA reports High cervical squamous staining; Medium Purkinje, cortical neuronal, esophageal squamous, gallbladder glandular and skin keratinocyte staining; and Low soft-tissue fibroblast staining (HPA tissue IHC). Select and score the actual cell population, rather than averaging a whole section (general IHC practice). |
| Nuclear distribution | NCOA7 is nuclear and cytoplasmic without estradiol and predominantly nuclear after estradiol stimulation (UniProt Q8NI08, PubMed:17391516). Hormone context may therefore inform a compartment comparison; the supplied HPA tissue data do not establish treatment-specific IHC intensity (HPA tissue IHC). |
| Golgi localisation | UniProt lists Rab-dependent recruitment to cis- and trans-Golgi network membranes by similarity (UniProt Q8NI08). HPA additionally approves Golgi localisation in ICC/IF (HPA subcellular ICC/IF). A Golgi-like pattern can be plausible, but it is not a required tissue IHC finding. |
| Isoforms and antibody coverage | UniProt lists 7 NCOA7 isoforms (UniProt Q8NI08). The payload supplies no antibody epitope or isoform coverage, so a negative stain cannot identify which isoform is absent; consult the selected antibody's documented specificity before making that inference (general IHC practice). |
| Evidence strength | HPA calls its tissue IHC reliability Approved while noting low agreement with RNA expression and pending external verification (HPA tissue IHC). Four listed antibodies have Approved IHC status; the supplied status alone does not validate every specimen or unexpected cell pattern (HPA antibodies; general IHC practice). |
| ICC/IF Q&A | What should ICC/IF show? Mainly nucleoplasm and nuclear bodies, with additional Golgi staining (HPA subcellular ICC/IF). That compartment evidence helps interpret localisation; it does not specify an IHC-P staining protocol (HPA subcellular ICC/IF). |
| Situation | Likely cause | Next action |
|---|---|---|
| No stain in a cervical squamous epithelial positive control. | The expected High cell-level signal is absent (HPA tissue IHC); the failed step cannot be identified from the supplied evidence. | Confirm the correct cells are present, then review the IHC-validated antibody's documented IHC-P conditions, retrieval, dilution and detection controls (general IHC practice). Do not infer NCOA7-specific fixation sensitivity; none is supplied. |
| Only a few cells stain in a tissue expected to be positive. | NCOA7 staining is cell-type dependent; HPA reports different levels even among listed positive populations (HPA tissue IHC). | Identify and score the named cell population—for example, Purkinje cells in cerebellum—against its reported Medium level, rather than treating the whole tissue as uniformly positive (HPA tissue IHC; general IHC practice). |
| Adipocytes or marrow hematopoietic cells stain strongly. | Both are reported Not detected (HPA tissue IHC); cross-reactivity or endogenous chromogenic detection activity is possible (general IHC practice). | Compare a detection-only negative control, check endogenous activity blocking and inspect the cell morphology; require concordant localisation before reporting NCOA7 (general IHC practice; HPA tissue IHC). |
| Background obscures nuclei and cell boundaries. | Non-specific antibody binding or detection background can obscure a cellular IHC pattern (general IHC practice). | Review blocking, antibody dilution, washes and the negative control using the antibody's documented IHC-P conditions; score only resolved cellular staining (general IHC practice). |
| Signal appears exclusively along cell membranes. | A border-only pattern conflicts with HPA's nuclear and cytoplasmic tissue profile and is not explained by a transmembrane segment (HPA tissue IHC; UniProt Q8NI08 topology). | Recheck the compartment under adequate magnification and compare controls; treat the border-only result as unconfirmed rather than assigning it to NCOA7 (general IHC practice). |
| A novel tissue pattern differs from the HPA example. | HPA reports low RNA–staining consistency and pending external verification despite an Approved tissue rating (HPA tissue IHC). | Record cell type, compartment and intensity, and seek independent antibody or orthogonal evidence before making a firm biological claim (general IHC practice). |
Experiment evidence
IHC & IF images showing NCOA7 staining
A05814-1 · IHCImmunohistochemical analysis of paraffin-embedded Human brain. Antibody was diluted at 1:100 (4° overnight). High-pressure and temperature T
A05814-2 · IHCFormalin-fixed and paraffin-embedded human brain tissue reacted with NCOA7 Antibody (N-term), which was peroxidase-conjugated to the seconda
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000111912-NCOA7/tissue/cerebral+cortex#imid_8754284
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000111912-NCOA7/tissue/colon#imid_8754218
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000111912-NCOA7/tissue/liver#imid_8754219
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000111912-NCOA7/tissue/kidney#imid_8754220
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA030292; green = NCOA7, blue = nucleus, red = microtubules.
HPA · ICC-IF U-251MGHuman Protein Atlas immunofluorescence, U-251MG, antibody HPA030292; green = NCOA7, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for NCOA7 IHC & IF
🧪Run cervix first and look for staining in its squamous epithelial cells (HPA: High in cervix squamous epithelial cells). Use adipose tissue adipocytes as the negative comparison (HPA: Not detected in adipocytes); on the cervix slide, assess other cell types for background, but do not assume they are NCOA7-negative because their staining is not specified in the supplied HPA row.
Positive control tissue: Cervix (Squamous epithelial cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show NCOA7 in A-431, U-251MG, U2OS, with annotated localisation: Nucleoplasm (approved), Nuclear bodies (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and an isotype control matched to the primary antibody’s host species and clonality (standard IHC practice). Use a knockout specimen if available or a peptide-block control as a biological specificity check (selected-SKU caption: immunogen-peptide pre-absorption); block endogenous peroxidase for chromogenic detection and assess tissue background (standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected-SKU paraffin-section caption does not state a fixative (selected-SKU caption: fixative not stated). The caption reports high-pressure, heated Tris-EDTA retrieval at pH 8.0 for human brain at 1:100 overnight at 4°C, but does not establish that retrieval is required for cervix (selected-SKU caption). Frozen sections and IF cannot be judged easier from the supplied evidence; the relevant cervix artefact to check is endogenous peroxidase background during chromogenic IHC (standard IHC practice).
HPA tissue IHC evidence for NCOA7
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cervix | Squamous epithelial cells | High | Protein (IHC) | HPA → |
| Cerebellum | Purkinje cells | Medium | Protein (IHC) | HPA → |
| Cerebral cortex | Neuronal cells | Medium | Protein (IHC) | HPA → |
| Esophagus | Squamous epithelial cells | Medium | Protein (IHC) | HPA → |
| Gallbladder | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced NCOA7 IHC Tips
Troubleshoot NCOA7 staining in paraffin sections by checking retrieval, compartment, cell identity, and controls before interpreting chromogenic signal.
How should I optimize retrieval when NCOA7 staining is weak in paraffin sections?
Use heat-mediated Tris-EDTA at pH 8.0 for antigen retrieval in paraffin sections (datasheet A05814-1). The selected brain image used high-pressure, high-temperature retrieval with that buffer and antibody at 1:100 overnight at 4°C (caption A05814-1). On adjacent sections, vary retrieval duration while holding antibody dilution and chromogen development constant, then compare both staining and tissue morphology (standard IHC practice). If staining remains weak, test citrate at pH 6.0 as a fallback on matched sections (standard IHC practice). Include the peptide-preabsorbed control when comparing conditions to identify nonspecific staining (caption A05814-1; standard IHC practice).
Can I adjust fixation to recover weak NCOA7 staining?
The selected paraffin brain caption does not report its fixative, so NCOA7-specific fixation sensitivity is unknown (caption A05814-1). Record the fixative, fixation duration, processing schedule, and section age for each specimen before attributing weak staining to fixation (standard IHC practice). Compare adjacent sections from the same block with heat-mediated Tris-EDTA at pH 8.0 and a constant antibody dilution to assess retrieval reproducibly (datasheet A05814-1; standard IHC practice). If specimen handling differs, process a documented reference section in the same run and compare staining with tissue preservation (standard IHC practice). Avoid treating any improvement after retrieval as proof of a particular NCOA7 fixation effect (standard IHC practice).
Should I score nuclear, cytoplasmic, or Golgi-like NCOA7 staining?
Score nuclear and cytoplasmic staining separately because both localisations are reported for NCOA7 (UniProt Q8NI08). Nucleoplasm and nuclear bodies are the main approved subcellular locations, with Golgi staining also reported (HPA subcellular). Estradiol stimulation can shift NCOA7 toward predominantly nuclear localisation, so document treatment conditions before comparing nuclear fractions across specimens (UniProt Q8NI08; PubMed:17391516). Assess Golgi-like staining as a distinct intracellular pattern rather than combining it with diffuse cytoplasmic signal (HPA subcellular; standard IHC practice). In chromogenic sections, use cell morphology and a consistent counterstain to assign compartments, and flag patterns that cannot be resolved confidently (standard IHC practice).
Could isoforms or epitope accessibility explain different staining patterns?
NCOA7 has 7 listed isoforms, so an antibody's recognised sequence matters when comparing staining across specimens (UniProt Q8NI08). The supplied caption does not identify the recognised epitope; therefore, it cannot establish which isoforms the catalog antibody detects (caption A05814-1; UniProt Q8NI08). The protein includes a LysM region at residues 114–157 and a TLDc region at 781–942, and listed modifications include phosphorylation (UniProt Q8NI08). Those features do not establish an epitope effect for this antibody (UniProt Q8NI08; caption A05814-1). Obtain the immunogen sequence if available, map it against isoforms, and compare retrieval conditions using matched sections before interpreting discordant staining (standard IHC practice).
How should I investigate NCOA7 localisation by multiplex IF?
Use the separate IF/ICC guide for the fluorescence workflow; this page's catalog evidence documents paraffin-section IHC (caption A05814-1). Multiplex NCOA7 with an independently validated marker for an expected cell type, such as Purkinje cells, and check that signals occupy the same cells (HPA tissue IHC; standard IF practice). Choose a far-red fluorophore when tissue autofluorescence obscures shorter wavelengths, and include single-channel controls to assess bleed-through (standard IF practice). NCOA7 has no transmembrane segment and has reported nuclear, cytoplasmic, and Golgi locations; select permeabilisation for the intracellular epitope being tested (UniProt Q8NI08; standard IF practice). Because that epitope is unspecified here, verify its accessibility experimentally (caption A05814-1; standard IF practice).
What controls help distinguish NCOA7 staining from chromogenic background?
Run a no-primary control to reveal secondary-reagent or detection background, and block endogenous peroxidase before DAB development (standard IHC practice). The selected brain image includes a peptide-preabsorbed antibody control, which can test whether staining depends on the immunogen-binding activity (caption A05814-1). Compare these controls with sections stained at the documented 1:100 dilution after Tris-EDTA retrieval at pH 8.0 (caption A05814-1; datasheet A05814-1). If diffuse chromogen obscures nuclei, shorten development or reduce antibody concentration while keeping matched controls in the run (standard IHC practice). Record counterstain strength and inspect tissue edges separately, since both can complicate compartment scoring (standard IHC practice).
How can I quantify NCOA7 without conflating cell abundance and staining intensity? ⚠ ANSWER MARKED FOR VERIFICATION
Define the tissue compartment and viable cell population before scoring, then use the same region-selection rules across sections (standard IHC practice). Report nuclear and cytoplasmic NCOA7 separately because both locations are documented, and keep Golgi-like puncta as a separate observation when resolvable (UniProt Q8NI08; HPA subcellular). For each compartment, record percent positive cells and intensity, or calculate an H-score on the 0–300 scale (standard IHC practice). Normalize counts to the number of eligible cells or positive-cell density to measured tissue area in mm², and report the denominator (standard IHC practice). Exclude necrotic and poorly preserved regions using rules set before scoring (standard IHC practice).
When is an apparent NCOA7-positive signal likely to be artefactual?
Interpret staining in its cellular context: nuclear and cytoplasmic expression is reported in several cell types, particularly within the CNS and squamous epithelia (HPA tissue IHC). An isolated extracellular deposit or signal confined to tissue edges deserves review against matched controls rather than immediate assignment to NCOA7 (standard IHC practice). Check necrotic areas and no-primary sections for chromogen deposition from tissue damage or endogenous enzyme activity (standard IHC practice). Compare the candidate positive cells with the expected morphology and, where appropriate, the peptide-preabsorbed control shown for the catalog antibody (HPA tissue IHC; caption A05814-1). Treat unexpected compartment or cell-type staining cautiously because tissue IHC reliability is approved with low RNA–protein consistency and pending external verification (HPA tissue IHC).
Boster reagents
Best NCOA7 / Nuclear receptor coactivator 7 IHC Antibodies
Two rabbit polyclonal anti-NCOA7 antibodies have human brain IHC images (catalog captions); both list human and mouse reactivity (catalog). One also lists IF, without an IF image (catalog: A05814-1).
Real IHC data
Anti-NCoA-7 Antibody
Cat # A05814-1
Real IHC data
Anti-NCOA7 Antibody (N-term)
Cat # A05814-2
A05814-1 has a human brain paraffin-section IHC image and lists IF, IHC, and human/mouse reactivity (catalog: A05814-1 caption and applications). A05814-2 has a formalin-fixed, paraffin-embedded human brain IHC image and lists IHC-P and human/mouse reactivity (catalog: A05814-2 caption and applications).
Which to pick: For tissue IHC, choose A05814-2 when paraffin-section paraffin sections match your sample; its own image documents that preparation and DAB detection (catalog: A05814-2 caption). For IF, choose A05814-1 because IF is listed at 1:50, while A05814-2 does not list IF; ICC performance is unreported (catalog: applications and dilutions). Both are rabbit polyclonals with listed human/mouse reactivity, but their IHC images show human brain only; A05814-1’s paraffin-section caption does not report the fixative (catalog: dilution_raw, reactivity, and captions). The selected A05814-1 tissue-IHC caption documents paraffin sections, but does not specify the fixative (selected-SKU IHC image A05814-1).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q8NI08 (NCOA7_HUMAN, Nuclear receptor coactivator 7).
- Human Protein Atlas. NCOA7 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. NCOA7 subcellular location (ICC-IF): Mainly localized to the nucleoplasm and nuclear bodies. In addition localized to the Golgi apparatus..
- Human Protein Atlas. NCOA7 antibody validation summary (4 antibodies).
- Expression of nuclear receptor co‑activator 7 protein is associated with poor prognosis of breast cancer. Oncology letters 2024 — PMC11063752.
- NCOA7 promotes OSCC progression by inhibiting ROS-regulated ferroptosis. Cellular and molecular life sciences : CMLS 2026 — PMC12819905.
- MALDI imaging reveals NCOA7 as a potential biomarker in oral squamous cell carcinoma arising from oral submucous fibrosis. Oncotarget 2016 — PMC5312364.
- Mapping the H(+) (V)-ATPase interactome: identification of proteins involved in trafficking, folding, assembly and phosphorylation. Scientific reports 2015 — PMC4595830.
- PubMed PMID:11971969 — UniProt-cited evidence.
- PubMed PMID:25330068 — UniProt-cited evidence.
- PubMed PMID:12880961 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for NCOA7 (Nuclear receptor coactivator 7). Expected localisation Nuclear and cytoplasmic staining (HPA tissue IHC). Antigen retrieval: Tris-EDTA pH 8.0 HIER, heat-mediated (datasheet A05814-1). Validated IHC antibody: A05814-1 at 1:100-1:300 (the product's own IHC validation image is shown). Controls (HPA): positive Cervix (Squamous epithelial cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Paraffin-embedded Human brain tissue; fixative not specified (datasheet A05814-1); 2. Fixation: Image fixative and duration unreported (datasheet A05814-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Tris-EDTA pH 8.0 (datasheet A05814-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-NCOA7, 1:100-1:300 (datasheet A05814-1); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A05814-1); Caveat: Staining and RNA show low consistency; validate specificity (HPA tissue IHC); Isoform / epitope: 7 isoforms; epitope coverage is unspecified (UniProt); Regulation: Estradiol promotes nuclear localization (UniProt). Evidence: UniProt Q8NI08, HPA tissue IHC · Approved, HPA ICC-IF · Mainly localized to the nucleoplasm and nuclear bodies. In addition…, Datasheet A05814-1, PMC11063752, PMC12819905. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/NCOA7/immunohistochemistry-ihc-guide.